Non Small Cell Lung Cancer Clinical Trials in East Brunswick, New Jersey

9 studies are recruiting for non small cell lung cancer in East Brunswick, New Jersey right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

   The goal of this clinical study is to learn more about the study drug, TUB-040, including its safety, tolerability, pharmacokinetics, and preliminary efficacy, and to determine the best dose of TUB-040 in participants with ovarian cancer or non-small cell lung cancer (NSCLC). The primary objectives…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START New Jersey (Astera Cancer Center), East Brunswick, New Jersey

   Locations

   21 in total

   Run by

   Gilead Sciences

   See if you can join NCT06303505 on ClinicalTrials.gov

2. Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

   This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to histological subtypes due to differences in chemotherapy choice…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Astera Cancer Care, East Brunswick, New Jersey

   Locations

   366 in total

   Run by

   BioNTech SE

   See if you can join NCT06712316 on ClinicalTrials.gov

3. A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to determine if telisotuzumab vedotin works better than …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Astera Cancer Care /ID# 257753, East Brunswick, New Jersey

   Locations

   317 in total

   Run by

   AbbVie

   See if you can join NCT04928846 on ClinicalTrials.gov

4. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

   This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Non-Small Cell Lung Cancer

   Stage

   Phase 2

   Ages

   18 and older

   Site

   START New Jersey, East Brunswick, New Jersey

   Locations

   24 in total

   Run by

   Verastem, Inc.

   See if you can join NCT07659782 on ClinicalTrials.gov

5. A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how safe telisotuzumab vedotin is in adult par…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Astera Cancer Care /ID# 272359, East Brunswick, New Jersey

   Locations

   83 in total

   Run by

   AbbVie

   See if you can join NCT06568939 on ClinicalTrials.gov

6. A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

   A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with locally advanced or metastatic HNSCC and to patients with any documented EGFR-mutant locally advanced or metastatic NSCLC.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Site 104 - START New Jersey, East Brunswick, New Jersey

   Locations

   8 in total

   Run by

   EpiBiologics

   See if you can join NCT07462377 on ClinicalTrials.gov

7. A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

   The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   AsteraCancer Care, East Brunswick, New Jersey

   Locations

   288 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT06793215 on ClinicalTrials.gov

8. A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

   Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan as a monotherapy or in combination with osimertinib compared to …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Astera Cancer Care /ID# 277570, East Brunswick, New Jersey

   Locations

   117 in total

   Run by

   AbbVie

   See if you can join NCT07155187 on ClinicalTrials.gov

9. ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

   The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for rec…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Astera Cancer Care, East Brunswick, New Jersey

   Locations

   57 in total

   Run by

   Guardant Health, Inc.

   See if you can join NCT05059444 on ClinicalTrials.gov